Antibiotic resistance in Helicobacter pylori has been a growing problem with current treatment regimens. However, second-line therapy for cases with eradication failure remains to be established. The aim of this study was to evaluate (in vitro) the potential use of rifampicin for H. pylori eradication. The susceptibility of 52 H. pylori strains isolated from children and adults to amoxicillin, clarithromycin, metronidazole and rifampicin was determined. Forty H. pylori isolates susceptible to these antibiotics were investigated for in vitro inducement of resistance. All isolates were susceptible to rifampicin. None of the H. pylori isolates tested acquired rifampicin resistance during prolonged exposure in in vitro inducement experiments. It is suggested that rifampicin has stable activity against H. pylori.
Introduction
Helicobacter pylori colonization is an important factor in the pathogenesis of chronic gastritis, peptic ulcers and gastric cancer. A combination of proton pump inhibitor and two antibiotics (new triple therapy) has been widely preferred as the standard regimen for eradicating H. pylori. At present, amoxicillin, clarithromycin and metronidazole are the antibiotics used most frequently in eradication regimens. 1 Adult studies have demonstrated that this new triple therapy achieves high eradication rates of between 80% and 90%. 2 On the other hand, H. pylori resistance to clarithromycin and metronidazole has been found worldwide, and is thought to be the major factor in eradication failure. 3 In strains isolated from patients with eradication failure, acquired resistance to the antibiotic used, especially clarithromycin, is frequently detected.
3 Efficient secondline therapy has not yet been established. Clarithromycin, a new macrolide, exhibits excellent antimicrobial activity against respiratory pathogens and consequently has commonly been used in both adult and paediatric populations; however, H. pylori shows cross-resistance among macrolides. 4 In contrast, in many countries, rifampicin is used almost exclusively for tuberculosis or atypical tuberculosis. There are fewer rifamycins in clinical use generally and there is only one preliminary study on the susceptibility of H. pylori to rifabutin. 5 In the present study, we investigated the in vitro susceptibility of H. pylori to rifampicin with the view that rifampicin is reserved as second-line therapy for the eradication of H. pylori. Inducement of resistance to each antibiotic (in vitro) was also determined.
Materials and methods

Patients and bacterial strains
A total of 52 patients underwent endoscopy and gastric biopsy because of gastrointestinal symptoms at Tohoku University Hospital and Social Insurance Sendai Hospital. Among these patients, 27 were paediatric patients aged 5-16 years. Diagnosis included chronic gastritis (n ϭ 15), gastric ulcer (n ϭ 25) and duodenal ulcer (n ϭ 12). Fiftytwo H. pylori strains were isolated from gastric biopsy samples. All patients had no previous history of treatment for H. pylori. Informed consent was obtained from all patients or their parents before inclusion in the study.
MIC determinations
Antimicrobial susceptibility was tested under microaerobic conditions (5% CO 2 , 5% O 2 , 90% N 2 ) for 72 h on MuellerHinton agar (Eiken, Tokyo, Japan) supplemented with 5%
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Results
MICs
MICs of each antibiotic for H. pylori are presented in the
In vitro inducement of drug resistance
For metronidazole, the MIC 90 rose gradually during in vitro drug resistance inducement procedures and acquired resistance after the ninth transfer (Figure) . These strains retained susceptibility to amoxicillin, clarithromycin and rifampicin during the inducement, although the MIC 90 of amoxicillin rose. In this study, the percentage of resistance to clarithromycin was significantly higher for children (41%) than for adults (4%) (P Ͻ 0.01). In children, macrolides including clarithromycin have frequently been used in the treatment of various diseases such as respiratory tract infections in clinical practice. This may be the reason for the high rate of clarithromycin resistance in H. pylori observed in children.
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Although the MIC breakpoint of rifampicin for H. pylori
has not yet been established, Heep et al. 6 reported that the MIC of rifampicin for resistant mutants of H. pylori ranged from 32 to 64 mg/L. This study demonstrated that the MIC of rifampicin for H. pylori remains low. No resistance to rifampicin was observed in any H. pylori strains studied. The concentration of rifampicin in gastric mucosa is 1.2 mg/L 12 h after administration of 450 mg of the drug. 9 Because the MIC range of rifampicin was Ͻ0.016-0.75 mg/L in this study, it is assumed that H. pylori would be susceptible to the usual dose of rifampicin in clinical practice. Furthermore, rifampicin is stable in acid and its side effects are infrequent. It can therefore be expected to exhibit a high degree of clinical efficacy.
The incidence of clarithromycin-resistant strains has increased in recent years. Rifampicin has retained its activity against clarithromycin-resistant isolates of H. pylori, and does not appear to induce drug resistance during prolonged exposure. These results suggest that rifampicin may be useful as second-line therapy in patients with eradication failure. One advantage of rifampicin is that the frequency of its clinical use is extremely low, allowing little opportunity for the development of resistance. Furthermore, we have reported that the prevalence of H. pylori infection is low in patients with tuberculosis and/or atypical tuberculosis who were treated with rifampicin. 10 Considering the data presented here and the results from in vitro inducement of resistance experiments, we believe that H. pylori strains would continue to be susceptible to rifampicin during therapy. However, further work would be required to establish efficacy.
